Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7955169 | 0.83 | SLC6A2 (0.43) | SLC6A3SLC6A2SLC6A4CHRNB4CHRNA3 | |
| SCHEMBL11712029 | 0.83 | NR4A1 (0.41) | SLC6A3SLC6A2SLC6A4ALDH1A1CHRNB4 | |
| SCHEMBL6182634 | 0.82 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4CHRNB4CHRNA3 | |
| SCHEMBL6182630 | 0.82 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4CHRNB4CHRNA3 | |
| SCHEMBL6757125 | 0.82 | CHRNB4 (0.50) | SLC6A3SLC6A2SLC6A4ALDH1A1CHRNB4 | |
| SCHEMBL8507027 | 0.81 | CHRNB2 (0.48) | CHRNB4CHRNA3 | |
| SCHEMBL11716273 | 0.80 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL11712930 | 0.80 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4GHSR | |
| SCHEMBL7406929 | 0.80 | CHRNB4 (0.36) | SLC6A3SLC6A2SLC6A4CHRNB4CHRNA3 | |
| SCHEMBL7411409 | 0.80 | CHRNB4 (0.36) | SLC6A3SLC6A2SLC6A4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SLC6A3 2511/4885SLC6A2 3510/4885SLC6A4 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.